Heron Therapeutics Inc (HRTX) VP Kimberly Manhard Sells 494 Shares

Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 494 shares of the business’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $30.62, for a total transaction of $15,126.28. Following the transaction, the vice president now owns 494 shares of the company’s stock, valued at approximately $15,126.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kimberly Manhard also recently made the following trade(s):

  • On Monday, October 1st, Kimberly Manhard sold 6,000 shares of Heron Therapeutics stock. The shares were sold at an average price of $32.07, for a total transaction of $192,420.00.

Shares of HRTX stock opened at $30.07 on Friday. Heron Therapeutics Inc has a 12 month low of $14.95 and a 12 month high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.14. The business had revenue of $17.28 million for the quarter, compared to analyst estimates of $12.82 million. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The firm’s revenue for the quarter was up 103.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.80) earnings per share. Analysts expect that Heron Therapeutics Inc will post -2.19 EPS for the current year.

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald restated a “buy” rating and set a $50.00 price objective on shares of Heron Therapeutics in a report on Wednesday, August 8th. ValuEngine lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 4th. Zacks Investment Research raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research note on Wednesday, July 18th. Stifel Nicolaus assumed coverage on shares of Heron Therapeutics in a research note on Thursday, September 13th. They issued a “buy” rating and a $55.00 price target on the stock. Finally, BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $52.09.

Several hedge funds have recently made changes to their positions in HRTX. BlackRock Inc. lifted its position in shares of Heron Therapeutics by 29.4% in the second quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock worth $176,563,000 after purchasing an additional 1,032,010 shares in the last quarter. FMR LLC lifted its position in shares of Heron Therapeutics by 6.5% in the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after purchasing an additional 693,699 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Heron Therapeutics in the second quarter worth $15,249,000. First Light Asset Management LLC lifted its position in shares of Heron Therapeutics by 76.8% in the second quarter. First Light Asset Management LLC now owns 836,737 shares of the biotechnology company’s stock worth $32,507,000 after purchasing an additional 363,462 shares in the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Heron Therapeutics in the second quarter worth $8,741,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Insider Buying and Selling by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply